{"entity":{"id":"nct06481592","kind":"trial","name":"A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.","aka":[],"tldr":"A phase 2 trial of Lifileucel in endometrial cancer, run by Iovance Biotherapeutics, Inc., now recruiting.","summary":"A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer. is a phase 2 interventional study registered as NCT06481592 by Iovance Biotherapeutics, Inc., with 60 participants planned, started 2024-10-29 and due to reach its primary completion in 2028-05. Interventions recorded: Lifileucel. Conditions listed: Endometrial Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06481592","url":"https://clinicaltrials.gov/study/NCT06481592"}],"tags":["ctgov-ingest"],"related":[],"cancers":["endometrial"],"sections":[],"technologies":[],"targets":[],"drugs":["lifileucel"],"companies":["iovance"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06481592","phase":"2","setting":"A Phase 2, Multicenter, Open-label Study of Lifileucel (Tumor-infiltrating Lymphocytes [TIL]) in Participants With Previously Treated Advanced Endometrial Cancer.","sponsor":"Iovance Biotherapeutics, Inc.","enrolled":60,"outcomes":[]},"route":"/trials/nct06481592/","neighbours":{"cancer":[{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"}],"drug":[{"id":"lifileucel","kind":"drug","name":"Lifileucel","route":"/drugs/lifileucel/"}],"company":[{"id":"iovance","kind":"company","name":"Iovance Biotherapeutics","route":"/companies/iovance/"}]}}